Best first-line therapy for patients with advanced non-small cell lung cancer, performance status 2 without a targetable mutation or with an unknown mutation status

Rolof G.P. Gijtenbeek; Kim de Jong; Ben J.W. Venmans; Femke H.M. van Vollenhoven; Anneke Ten Brinke; Anthonie J. Van der Wekken; Wouter H. van Geffen

doi:10.1002/14651858.CD013382

Best first-line therapy for patients with advanced non-small cell lung cancer, performance status 2 without a targetable mutation or with an unknown mutation status

Rolof G.P. Gijtenbeek^*, Kim de Jong, Ben J.W. Venmans, Femke H.M. van Vollenhoven, Anneke Ten Brinke, Anthonie J. Van der Wekken, Wouter H. van Geffen

^*Corresponding author for this work

Damage and Repair in Cancer Development and Cancer Treatment (DARE)

Research output: Contribution to journal › Article › Academic › peer-review

5 Downloads (Pure)

Abstract

This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: To identify the best first-line therapy for advanced lung cancer in patients with performance status 2 without a targetable mutation or with an unknown mutation status.

Original language	English
Article number	CD013382
Number of pages	14
Journal	Cochrane Database of Systematic Reviews
Volume	2019
Issue number	8
DOIs	https://doi.org/10.1002/14651858.CD013382
Publication status	Published - 12-Aug-2019

Access to Document

10.1002/14651858.CD013382

Best first‐line therapy for patients with advanced non‐small cell lung cancer, performance status 2 without a targetable mutation or with an unknown mutation status Final publisher's version, 497 KBLicence: Taverne

Handle.net

Persistent link

Cite this

Gijtenbeek, R. G. P., de Jong, K., Venmans, B. J. W., van Vollenhoven, F. H. M., Brinke, A. T., Van der Wekken, A. J., & van Geffen, W. H. (2019). Best first-line therapy for patients with advanced non-small cell lung cancer, performance status 2 without a targetable mutation or with an unknown mutation status. Cochrane Database of Systematic Reviews, 2019(8), [CD013382]. https://doi.org/10.1002/14651858.CD013382

@article{59a8668e08124a4b8b62f04a23d7c615,

title = "Best first-line therapy for patients with advanced non-small cell lung cancer, performance status 2 without a targetable mutation or with an unknown mutation status",

abstract = "This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: To identify the best first-line therapy for advanced lung cancer in patients with performance status 2 without a targetable mutation or with an unknown mutation status.",

author = "Gijtenbeek, {Rolof G.P.} and {de Jong}, Kim and Venmans, {Ben J.W.} and {van Vollenhoven}, {Femke H.M.} and Brinke, {Anneke Ten} and {Van der Wekken}, {Anthonie J.} and {van Geffen}, {Wouter H.}",

year = "2019",

month = aug,

day = "12",

doi = "10.1002/14651858.CD013382",

language = "English",

volume = "2019",

journal = "Cochrane database of systematic reviews (Online)",

issn = "1469-493X",

publisher = "Wiley",

number = "8",

}

Gijtenbeek, RGP, de Jong, K, Venmans, BJW, van Vollenhoven, FHM, Brinke, AT, Van der Wekken, AJ & van Geffen, WH 2019, 'Best first-line therapy for patients with advanced non-small cell lung cancer, performance status 2 without a targetable mutation or with an unknown mutation status', Cochrane Database of Systematic Reviews, vol. 2019, no. 8, CD013382. https://doi.org/10.1002/14651858.CD013382

Best first-line therapy for patients with advanced non-small cell lung cancer, performance status 2 without a targetable mutation or with an unknown mutation status. / Gijtenbeek, Rolof G.P.; de Jong, Kim; Venmans, Ben J.W. et al.

In: Cochrane Database of Systematic Reviews, Vol. 2019, No. 8, CD013382, 12.08.2019.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Best first-line therapy for patients with advanced non-small cell lung cancer, performance status 2 without a targetable mutation or with an unknown mutation status

AU - Gijtenbeek, Rolof G.P.

AU - de Jong, Kim

AU - Venmans, Ben J.W.

AU - van Vollenhoven, Femke H.M.

AU - Brinke, Anneke Ten

AU - Van der Wekken, Anthonie J.

AU - van Geffen, Wouter H.

PY - 2019/8/12

Y1 - 2019/8/12

N2 - This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: To identify the best first-line therapy for advanced lung cancer in patients with performance status 2 without a targetable mutation or with an unknown mutation status.

AB - This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: To identify the best first-line therapy for advanced lung cancer in patients with performance status 2 without a targetable mutation or with an unknown mutation status.

U2 - 10.1002/14651858.CD013382

DO - 10.1002/14651858.CD013382

M3 - Article

AN - SCOPUS:85072052341

SN - 1469-493X

VL - 2019

JO - Cochrane database of systematic reviews (Online)

JF - Cochrane database of systematic reviews (Online)

IS - 8

M1 - CD013382

ER -